To evaluate the role of granulocyte colony-stimulating factor (G-CSF) as adjunctive therapy for the treatment of diabetic foot infections in non-neutropenic patients.
DATA SOURCES
Clinical literature was accessed through MEDLINE (1965–April 2004). Key search terms included G-CSF, infection, and diabetes. In addition, relevant references from primary and secondary article bibliographies were extracted.
DATA SYNTHESIS
Three clinical trials evaluating G-CSF for diabetic foot infections were identified. These data demonstrated positive effects of G-CSF on improvement of foot infections and risk of amputations.
CONCLUSIONS
Controlled trials are necessary to validate the role of adjunctive G-CSF at reducing amputations in patients with diabetic foot infections.
. DeLallaF, PellizzerG, StrazzaboscoM, MartiniZ, Du JardinG, LoraL, Randomized prospective controlled trial of recombinant granulocyte colony-stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection. Antimicrob Agents Chemother2001; 45: 1094–8.
9.
. YonemA, CakirB, GulerS, AzalOO, CorakciA. Effects of granulocyte-colony stimulating factor in the treatment of diabetic foot infection. Diabetes Obes Metab2001; 3: 332–7.
10.
. StullDM. Colony-stimulating factors: beyond the effects on hematopoiesis. Am J Health Syst Pharm2002; 59 (7 suppl 2): S12–20.
11.
. NathanCF. Respiratory burst in adherent human neutrophils: triggering by colony-stimulating factors CSF-GM and CSF-F. Blood1989; 73: 301–6.
12.
. YongKL, LinchDC. Differential effects of granulocyte- and granulocyte-macrophage colony-stimulating factors (G- and GM-CSF) on neutrophil adhesion in vitro and in vivo. Eur J Haematol1992; 49: 251–9.
13.
. WangJM, ColellaS, AllavenaP, MantovaniA. Chemotactic activity of human recombinant granulocyte-macrophage colony-stimulating factor. Immunology1987; 138: 439–44.
14.
. WeisbartRH, KwanL, GoldeDW, GassonJC. Human GM-CSF primes neutrophils for enhanced oxidative metabolism in response to the major physiological chemoattractants. Blood1987; 69: 18–21.
15.
. FleischmannJ, GoldeDW, WeisbartRH, GassonJC. Granulocyte-macrophage colony-stimulating factor enhances phagocytosis of bacteria by human neutrophils. Blood1986; 68: 708–11.
16.
. GeerlingsSE, HoepelmanA. Immune dysfunction in patients with diabetes mellitus. FEMS Immunol Med Microbiol1999; 26: 259–65.
17.
. HudsonBI, BucciarelliLG, WendtT, SakaguchiT, LallaE, QuW, Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders. Arch Biochem Biophys2003; 419: 80–8.
18.
. CollisonKS, ParharRS, SalehSS, MeyerBF, KwaasiAA, HammamiMM, RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs). J Leukoc Biol2002; 71: 433–44.
19.
. FrykbergRG. An evidence-based approach to diabetic foot infections. Am J Surg2003; 186 (5A): 44S–54S.
20.
. LipskyBA, BerendtAR. Principles and practice of antibiotic therapy of diabetic foot infections. Diabetes Metab Res Rev2000; 16 (suppl 1): S42–6.
